Select Page



Ted Hisokawa
Sep 06, 2024 02:56

Injective (INJ)collaborates with Mercuryo to streamline user onboarding through a new fiat on-ramp payment solution.





Injective, a prominent blockchain platform, has announced a strategic partnership with Mercuryo, a leading fiat on-ramp payment solutions provider. This collaboration aims to simplify the onboarding process for new users, enabling them to engage with the Injective (INJ)ecosystem more efficiently, according to the Injective Blog.

Streamlined User Onboarding

The partnership focuses on leveraging Mercuryo’s robust fiat on-ramp capabilities to facilitate seamless entry into the Injective platform. Users can now purchase digital assets directly using their local currencies, bypassing the often complex and cumbersome traditional methods. This integration is expected to enhance user experience and broaden the accessibility of Injective’s decentralized finance (DeFi) services.

Enhanced Accessibility

By incorporating Mercuryo’s payment solutions, Injective aims to lower the barriers to entry for new users. The fiat on-ramp service supports multiple payment methods, including credit and debit cards, making it easier for users worldwide to join the Injective network. This move aligns with Injective’s broader mission to democratize access to financial services through blockchain technology.

Recent Developments

September has been a busy month for Injective. Alongside the Mercuryo partnership, the platform has rolled out a significant chain upgrade, enhancing its overall performance and security. Additionally, Injective has been active on the conference circuit, showcasing its latest innovations and forging new industry connections.

Future Prospects

The collaboration with Mercuryo is expected to drive substantial growth for Injective by attracting a more diverse user base. As blockchain technology continues to gain mainstream adoption, partnerships like these are crucial for bridging the gap between traditional finance and the burgeoning DeFi sector.

For more information, visit the Injective Blog.

Image source: Shutterstock


Share it on social networks